|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/9/2013 7:46:04 AM
Jeremy Levin did not give a pass to all 46,000 employees of Teva Pharmaceuticals Ltd., but some might be happy to hear that the chief executive officer said Tuesday that reducing "head count" will play only a "small role" in the company's plans to cut $1.5 billion to $2 billion in costs in the next five years. Teva is based in Israel but has its Americas headquarters in North Wales, as well as facilities in Horsham, Frazer, Sellersville, and several New Jersey locations. Indeed, part of Levin's concern since taking over as CEO on May 9 has been that the company has 74 locations in 120 countries and that its efforts were not properly focused. "Not in any way will this be spreading the peanut butter," Levin said in a discussion with stock market analysts Tuesday at the J.P. Morgan Chase Healthcare Conference in San Francisco. Levin was named to his position on Jan. 1, 2012, in part because the Teva stock had languished in recent years. It closed Tuesday up 0.19, at 38.25. Among the projects for which planning "ceased" was a $300 million facility in Northeast Philadelphia that was to serve distribution, warehousing and computer functions. Levin tried again Tuesday to encourage analysts to recommend the stock to clients, though several have said they were lukewarm about the company's generic- and branded-pharmaceuticals pipeline and had no clear indication that the billions in savings would translate into profits. The $6.8 billion purchase of Frazer-based Cephalon in 2011 was one of the larger of the acquisitions that form today's Teva. Though Teva laid off about 1,500 Cephalon employees in Europe almost immediately, acquisitions can add other redundant costs.
|
|
|
|
|
|
|
|
|
|
|